Dade Behring Signs License and Research Agreements Related to Development of New Coagulation Test.

DEERFIELD, Ill. -- Dade Behring Inc. (NASDAQ:DADE) today announced that it has signed a license agreement with Radboud University Nijmegen Medical Centre (RUNMC) granting Dade Behring with the exclusive rights for a new coagulation test called the Nijmegen Hemostasis Assay (NHA), anticipated by researchers at RUNMC to become accepted for testing a broad range of coagulation disorders. A research agreement was also signed granting Dade Behring with the rights to results from future NHA research and development performed by RUNMC.

"These agreements reaffirm Dade Behring's commitment to developing innovative tests that impact the future of clinical diagnostics and patient care," said Jim Reid-Anderson, Chairman, President and CEO, Dade Behring. "Dade Behring has been a pioneer of coagulation testing for more than thirty years and we continue to focus on developing our leadership position in this market by collaborating with institutions to further enhance our broad portfolio of tests."

Hemostasis is a complex process in which multiple components regulate blood flow and clot formation. Coagulation, fibrinolysis and platelet aggregation are a part of this process. The NHA is viewed by researchers to be important because it could provide insight into the whole blood-clotting process--simultaneously in one test. This type of test is commonly called a "global" test, referring to its potential for screening a broad range of coagulation disorders including thrombophilia and fibrinolytic abnormalities1,2.

Research presented at recent scientific conferences has shown a trend towards the use of "global" coagulation testing. The scientific and medical communities believe such methodology may enable clinicians to better understand the complete blood clotting process in a patient. In some cases, this could eliminate the need to isolate and test for separate components of the process3,4. It is also believed that this type of test may mimic the true in-vivo scenario of blood clotting in the human body.

"Global tests reflecting the regulation of the hemostatic balance in patients are promising tools to better assess the needs of patients," said Waander van Heerde, Ph.D., principle investigator, Thrombosis Hemostasis Research Organization Radboud. "We are very delighted that Dade Behring is collaborating with us--together we expect to further extend the knowledge of global testing for thrombosis and hemostasis. The global NHA test not only has the potential to give answers about the clinical picture of the patient, but may also be used to monitor therapy efficacy and pre-clinical studies."

About Dade Behring Hemostasis (coagulation and platelet function testing)

With more than 30 years of experience, the company is committed to ongoing development of coagulation assays to assess bleeding and thrombotic risk. Dade Behring has many "firsts" in the coagulation industry, including pioneering the first routine coagulation test using recombinant tissue factor--Innovin([R]) reagent for the prothrombin time test. The company also developed the first automated ristocetin cofactor activity test that detects Von Willebrand disease, which is the most common inherited bleeding disorder. Dade Behring is the largest provider of hemostasis analyzers in the world and has a leading position in automated platelet function analysis.

About Dade Behring Inc.

With 2005 revenue of nearly $1.7 billion, Dade Behring is the world's largest company solely dedicated to clinical diagnostics. It offers a wide range of products, systems and services designed to meet the day-to-day needs of laboratories, delivering innovative solutions to customers and enhancing the quality of life for patients. Additional company information is available on the Internet at www.dadebehring.com.

About Radboud University Nijmegen Medical Centre (RUNMC)

Radboud University Nijmegen Medical Centre, located in the Netherlands, is a leading academic centre with expertise in medical science and healthcare. Expertise plays an essential part in the organization and connects research, education and patient care. The more than 8,500 staff and 2,500 students are committed and ambitious, helping to shape the future of healthcare and medical science. Radboud University Nijmegen Medical Centre is driven by knowledge, empowered by people. Additional information is available on the Internet at www.umcn.nl/scientist.

1. Journal of Thrombosis and Haemostasis 2005; Volume 3, Supplement 1: abstract number P1870

2. Haemophilia (2006), 12 (Supplement2); PO 189

3. Journal of Thrombosis and Haemostasis 2005; Volume 3, Supplement 1: abstract number P2378

4. Journal of Thrombosis and Haemostasis 2005: Volume 3, Supplement 1: abstract number P1373

This press release may contain "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward statements include information regarding the intent, belief or current expectation of the company and members of its senior management team, including, without limitation, expectations regarding prospective performance and opportunities and the outlook for the company's businesses, performance, opportunities and regulatory approval. In addition, the company is in the process of a major new product launch, which involves risks and uncertainties regarding product performance, costs of introduction and support, and customer acceptance. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by the company.